Table 2. Capecitabine-specific skin toxicity – correlation with response.
|
Grade 0, (n=101) (67.8%)
a
|
Grade 1–3, (n=48) (32.2%)
a
|
P-value, Fisher's exact test (two-sided) | |||
|---|---|---|---|---|---|
| n | % | n | % | ||
| Complete remission (CR)b | 5 | 5.0 | 3 | 6.3 | 0.713 |
| Partial remission (PR)b | 50 | 49.5 | 25 | 52.1 | 0.861 |
| Stable disease (SD)b | 32 | 31.7 | 19 | 39.6 | 0.361 |
| Progressive disease (PD)b | 14 | 13.9 | 1 | 2.1 | 0.038 |
| Overall response rate (ORR)b | 55 | 54.5 | 28 | 58.3 | 0.725 |
| Disease control rate (DCR)b | 87 | 86.1 | 47 | 97.9 | 0.038 |
a
According to the National Cancer Institute Common Toxicity Criteria of Adverse Events, version 3.0.
b
According to the RECIST criterion.